Results 11 to 20 of about 1,950 (155)

Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study

Renal Failure, 2023
Purpose This cohort study was designed to explore whether roxadustat or erythropoietin could affect thyroid function in patients with renal anemia.Methods The study involved 110 patients with renal anemia. Thyroid profile and baseline investigations were
Xiaomeng Zheng, Yiyi Jin, Tao Xu, Hongbin Xu, Suyan Zhu   +4 more
doaj   +3 more sources

Roxadustat alleviates cisplatin-induced acute kidney injury by regulating fatty acid oxidation and mitochondrial function

Renal Failure
Aims This study aimed to elucidate the role and function of roxadustat, a small molecule hypoxia-inducible factor (HIF) stabilizer, on cisplatin-induced acute kidney injury (AKI) in vivo and in vitro.Methods We investigated the effects of roxadustat (10 ...
Xialin Li, Yan Hu, Jinqing Li, Yingfeng Shi, Qin Zhong, Xiaoyan Ma, Daofang Jiang, Shasha Zhang, Shougang Zhuang, Na Liu   +9 more
doaj   +2 more sources

Roxadustat effectiveness versus ESAs in peritoneal dialysis patients during the COVID-19 pandemic: A retrospective study.

PLoS ONE
BackgroundThe COVID-19 pandemic has made treating renal anemia in chronic kidney disease (CKD) patients undergoing peritoneal dialysis (PD) difficult. The current study aims to compare roxadustat with erythropoiesis-stimulating agents (ESAs) during the ...
Jie Liu, Kefan Zhou, Chen Meng, Zhuzhu Liu, Ruihua Huang, Yousuf Waheed, Fan Yang, Kun Liu, Jiaqi Zhao, Lin Zhang, Xiaoyan Yu, Shuang Li, Tianyu Li, Yanshan Tong, Xiaodan Wei, Chuankuo Tian, Dong Sun, Xinglei Zhou   +17 more
doaj   +2 more sources

A Case Report of Hypothyrotropin Hypothyroidism Caused by Roxadustat

Xiehe Yixue Zazhi
Roxadustat is the world's first small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor. Its adverse effect of causing hypothyroidism with low thyroid-stimulating hormone (TSH) is relatively rare and manifests subtly in elderly patients with
YAN Xuelian, TANG Bingying, QU Xuan, ZHANG Ning, KANG Lin   +4 more
doaj   +2 more sources

A critical review of Roxadustat formulations, solid state studies, and analytical methodology

Heliyon, 2023
This review aims to collate information about the analytical methodologies, bioanalytical methodologies, pharmaceutical formulations, solid-state studies, and the current and future market scenario for a relatively new class of drugs, Roxadustat ...
Rupali Mahajan, Gananadhamu Samanthula, Saurabh Srivastava, Amit Asthana   +3 more
doaj   +2 more sources

The HIFα-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1⁺ Cells [PDF]

Cells, 2022
Inhibition of the prolyl-4-hydroxylase domain (PHD) enzymes, leading to the stabilization of hypoxia-inducible factor (HIF) α as well as to the stimulation of erythropoietin (Epo) synthesis, is the functional mechanism of the new anti-anemia drug ...
Aline Jatho, Anke Zieseniss, Katja Brechtel-Curth, Jia Guo, Kai Oliver Böker, Gabriela Salinas, Roland H. Wenger, Dörthe M. Katschinski   +7 more
doaj   +2 more sources

Roxadustat promotes allograft recovery after kidney transplantation: A prospective, multicenter, randomized controlled trial

Asian Journal of Surgery
Background: Kidney transplantation is the most effective treatment for end-stage kidney disease. However, delayed graft function (DGF) remains a common complication. Roxadustat effectively treats renal anemia and ameliorates acute kidney injury. However,
Mao-Lin Ma, Fei Han, Lei Zhang, Zheng-Yu Huang, Tao Zhang, Heng Li, Jia-Li Fang, Zheng Chen, Ning Na   +8 more
doaj   +2 more sources

Early Post-Kidney Transplant Treatment With Roxadustat Ameliorates Anemia and Reduces Blood Transfusion Needs in Inflamed Patients: A Case-Matched Study. [PDF]

Clin Transplant
ABSTRACT Background Roxadustat is an oral hypoxia‐inducible factor prolyl‐hydroxylase inhibitor. Recent studies have shown no inferiority of roxadustat compared to erythropoietin in chronic kidney disease and in post‐transplant patients. We evaluated roxadustat versus erythropoiesis‐stimulating agents (ESAs) in very early posttransplant patients ...
Randone P, Valenza L, Mella A, Fop F, Dolla C, Gallo E, Manzione AM, Mingozzi S, Tarragoni R, Sanna E, Biancone L.   +10 more
europepmc   +2 more sources

Optimising Haematopoietic Stem Cell Transplantation: Enhancing Myeloablation Sensitivity and Alleviating Anaemia Using Roxadustat (FG-4592). [PDF]

Cell Prolif
The use of FG‐4592 in the process of myeloablation can promote haematopoietic cell apoptosis for more effective myeloablation, maintain the number of RBC and may create a pluripotent microenvironment suitable for donor cells, so as to enable more effective haematopoietic reconstruction of donor cells in vivo.
Yang G, Wu J, Guo X, Shen W, Sang X, Gong X, Huang SZ, Zhang J, Zeng F.   +8 more
europepmc   +2 more sources

Roxadustat-Associated Cholestatic Jaundice in Haemodialysis Patients with Positive Rechallenge. [PDF]

Eur J Case Rep Intern Med
Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is widely used for anaemia in chronic kidney disease. While pivotal trials reported low risks of transaminase elevations, detailed clinical case reports substantiating a causal ...
Ke X, Liu C.
europepmc   +2 more sources